A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.

Sayegh L.; Rufiange M.; Sadoune A. Ait; Sicard E.; Massicotte J.; Lefebvre M.; Colin P.; Ranger M.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.

【24h】

A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.

机译：一阶段适应性设计研究，旨在评估健康志愿者中GIC-1001单次口服口服剂量的安全性，耐受性和药代动力学。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2014年第1期|共2页
作者
Sayegh L.; Rufiange M.; Sadoune A. Ait; Sicard E.; Massicotte J.; Lefebvre M.; Colin P.; Ranger M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS. [J] . Sayegh L., Rufiange M., Sadoune A. Ait, Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：一阶段适应性设计研究，旨在评估健康志愿者中GIC-1001单次口服口服剂量的安全性，耐受性和药代动力学。
2. Safety, Tolerability and Pharmacokinetics of Trimebutine 3-Thiocarbamoylbenzenesulfonate (GIC-1001) in a Randomized Phase I Integrated Design Study: Single and Multiple Ascending Doses and Effect of Food in Healthy Volunteers [J] . Paquette Jean-Michel, Rufiange Marianne, Niculita Mirela Iovu, Clinical therapeutics . 2014,第11期

机译：曲美布汀3-硫代氨基甲酰基苯磺酸盐（GIC-1001）的随机I期集成设计研究的安全性，耐受性和药代动力学：健康志愿者中的单次和多次递增剂量及食物的作用
3. STUDY DESIGN OF A PHASE I, PLACEBO-CONTROLLED, FIRST-INHUMAN TRIAL TO ASSESS SAFETY AND TOLERABILITY, IMMUNOGENICITY, AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF THE ANTI-ADAMTS-5 NANOBODY (R), M6495, IN HEALTHY MALE SUBJECTS [J] . Balchen T., Strotmann R., Bihlet A. Reinstrup, Osteoarthritis and cartilage . 2018,第Suppla1期

机译：研究I阶段，安慰剂控制，第一inhuman试验，以评估抗Adamts-5纳米胸（R），M6495，健康男性受试者的单一升序剂量，免疫原性和药代动力学和药效学和药效学
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Pharmacokinetics, tissue depletion, target animal safety and live animal swab test accuracy after administration of long-acting oxytetracycline at double the label dose in healthy calves. [D] . TerHune, Terry Norman. 1988

机译：在健康小牛中，以双倍剂量服用长效土霉素后，药代动力学，组织耗竭，目标动物安全性和活体拭子测试准确性。
6. A first-in-human randomized double-blind placebo-controlled single and multiple ascending oral dose study to assess the safety tolerability and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers [O] . Stephen Youngberg, Erin Brandt, Avantika Barve, 2018

机译：一项首次在人类中进行的随机双盲安慰剂对照单次和多次递增口服剂量研究以评估含或不含利托那韦的BZF961在健康成人志愿者中的安全性耐受性和药代动力学
7. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers [O] . 2014

机译：新型螺螺吲哚酮KAE609的首次人类随机，双盲，安慰剂对照，单次和多次递增口服剂量研究，以评估健康成人志愿者的安全性，耐受性和药代动力学

A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.

著录项

相似文献

相关主题

期刊订阅